| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lecithin — a heterogeneous mixture of phospholipids (primarily phosphatidylcholine [PC], phosphatidylethanolamine [PE], phosphatidylinositol [PI], phosphatidylserine [PS]) derived from soy, sunflower, egg yolk, or marine sources. Used as a dietary supplement, emulsifier, and drug-delivery excipient. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Orally digested to lysophospholipids + choline; re-esterified and incorporated into lipoproteins/cell membranes. Systemic effects reflect nutrient flux, not direct pharmacologic signaling. In-vitro vs oral exposure: Many membrane or apoptosis effects seen in vitro are concentration-dependent and not reflective of typical dietary intake. Clinical evidence status: Nutritional supplement; evidence strongest for hepatic lipid metabolism and choline deficiency states. No validated anti-cancer indication. Lecithin a phospholipid-rich compound (often derived from soy or sunflower), can enhance the bioavailability of certain lipophilic (fat-soluble) and amphipathic compounds by improving their solubility, absorption, and cellular uptake.Supplements and Compounds with Improved Bioavailability via Lecithin Curcumin Up to 20–30x better absorption in some formulations Quercetin Resveratrol Silybin (from milk thistle) Green tea catechins, EGCG Lecithin helps stabilize and protect catechins during digestion Boswellic acids Coenzyme Q10 (CoQ10) Omega-3 fatty acids Vitamin D, E, A, K (Fat-soluble vitamins) Alpha-lipoic acid (ALA) black seed oil (Nigella sativa) and its key active compound, thymoquinone. Lecithin — Cancer vs Normal Cell Pathway Map
TSF legend: |
| Source: |
| Type: |
| Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells. The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment. Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS). – In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer. • Expression Patterns in Tumors: – Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment. – Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation. |
| 1792- | CUR, | LEC, | Chondroprotective effect of curcumin and lecithin complex in human chondrocytes stimulated by IL-1β via an anti-inflammatory mechanism |
| - | in-vitro, | Arthritis, | RAW264.7 | - | NA, | NA, | HCC-38 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:114 Target#:563 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid